Sagimet Biosciences: Innovations Against Metabolic Disorders

Sagimet Biosciences, a clinical-stage biopharmaceutical company, is dedicated to the development of therapeutics known as fatty acid synthase inhibitors (FASN). These inhibitors target the treatment of diseases resulting from disrupted metabolic pathways. The company's most promising drug candidate is Denifanstat. This once-daily pill is a selective FASN inhibitor used for the treatment of metabolic dysfunctions associated with steatohepatitis. In addition to Denifanstat, the company is working on TVB-3567, another FASN inhibitor developed for combating acne. Formerly known as 3-V Biosciences, the company was renamed Sagimet Biosciences in August 2019. Since its founding in 2006, Sagimet has established its headquarters in San Mateo, California.